Literature DB >> 16490362

A review of WHO International Standards for botulinum antitoxins.

R G A Jones1, M J Corbel, D Sesardic.   

Abstract

Clostridium botulinum produces the most potent known toxins, with seven distinct serotypes currently defined (A-G). These toxins can cause a life threatening systemic toxicity whether through natural causes such as food poisoning, infant botulism, wound botulism, or through use as bio-terror agents (e.g. inhalational botulism). It was realised early on that standard reference botulinum antitoxins were required to reduce the variation between assays and ensure a consistent potency of therapeutic antitoxins and vaccines, and to define the serotype. This led to the International Unit being defined by the World Health Organisation (WHO) in the 1960s with the establishment of the first International Standards (IS) for serotypes A-F. Since then botulinum antitoxin ISs have been used world wide as the 'yard stick' to measure the neutralising potency of antitoxins. These primary WHO ISs are used to calibrate in house working reagents that are more extensively utilised. A definition of the International Unit for serotype G antitoxin has yet to be defined or accepted by the WHO and urgently needs addressing. However, before September 11th 2001 there was very little interest in botulinum antitoxin IS and as a result stocks of most of the original preparations are now completely exhausted or depleted and replacements long overdue. We have reviewed the extensive history and availability of the primary WHO ISs and interim materials. All type A and B antitoxin materials were recently assayed and their relative activities confirmed against the original IS preparations. The recent increase in demand for these materials has further exacerbated the shortage. We describe here the production and characterization of stable freeze dried potential candidate replacements along with a new prospective first IS for type G antitoxin. Available toxin A reference preparations are also briefly reviewed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16490362     DOI: 10.1016/j.biologicals.2005.11.009

Source DB:  PubMed          Journal:  Biologicals        ISSN: 1045-1056            Impact factor:   1.856


  7 in total

1.  Vaccination of rabbits with an alkylated toxoid rapidly elicits potent neutralizing antibodies against botulinum neurotoxin serotype B.

Authors:  Daniel M Held; Amy C Shurtleff; Scott Fields; Christopher Green; Julie Fong; Russell G A Jones; Dorothea Sesardic; Roland Buelow; Rae Lyn Burke
Journal:  Clin Vaccine Immunol       Date:  2010-04-21

2.  A Novel Botulinum Neurotoxin, Previously Reported as Serotype H, Has a Hybrid-Like Structure With Regions of Similarity to the Structures of Serotypes A and F and Is Neutralized With Serotype A Antitoxin.

Authors:  Susan E Maslanka; Carolina Lúquez; Janet K Dykes; William H Tepp; Christina L Pier; Sabine Pellett; Brian H Raphael; Suzanne R Kalb; John R Barr; Agam Rao; Eric A Johnson
Journal:  J Infect Dis       Date:  2015-06-10       Impact factor: 5.226

3.  Preparation of egg yolk antibodies against BoNT/B and their passive protection in mouse models.

Authors:  Zherong You; Hao Yang; Wenwen Xin; Lin Kang; Shan Gao; Junhong Wang; Tao Zhang; Jinglin Wang
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

4.  Characterization of new formalin-detoxified botulinum neurotoxin toxoids.

Authors:  James E Keller
Journal:  Clin Vaccine Immunol       Date:  2008-07-30

5.  Transsynaptic inhibition of spinal transmission by A2 botulinum toxin.

Authors:  Norio Akaike; Min-Chul Shin; Masahito Wakita; Yasushi Torii; Tetsuhiro Harakawa; Akihiro Ginnaga; Keiko Kato; Ryuji Kaji; Shunji Kozaki
Journal:  J Physiol       Date:  2012-10-29       Impact factor: 5.182

6.  In vivo neutralization of botulinum neurotoxins serotype E with heavy-chain camelid antibodies (VHH).

Authors:  Hamid Bakherad; Seyed Latif Mousavi Gargari; Iraj Rasooli; Masoumeh Rajabibazl; Mohammad Mohammadi; Walead Ebrahimizadeh; Leila Safaee Ardakani; Hamed Zare
Journal:  Mol Biotechnol       Date:  2013-10       Impact factor: 2.695

7.  New equine antitoxins to botulinum neurotoxins serotypes A and B.

Authors:  D Li; P Mattoo; J E Keller
Journal:  Biologicals       Date:  2012-05-05       Impact factor: 1.856

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.